Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study
ObjectiveTo investigate the clinical efficacy of holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH) with prostatic inflammation (PI).MethodsWe prospectively collected and followed up data on patients with BPH who underwent HoLEP at the Affiliated...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.1026657/full |
| _version_ | 1797960127966347264 |
|---|---|
| author | Weijian Zhou Dongdong Mao Liang Li Gang Liu Guojun Gao Haikun Li Dianjun Gao |
| author_facet | Weijian Zhou Dongdong Mao Liang Li Gang Liu Guojun Gao Haikun Li Dianjun Gao |
| author_sort | Weijian Zhou |
| collection | DOAJ |
| description | ObjectiveTo investigate the clinical efficacy of holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH) with prostatic inflammation (PI).MethodsWe prospectively collected and followed up data on patients with BPH who underwent HoLEP at the Affiliated Hospital of Weifang Medical University between July 2021 and July 2022. According to the postoperative pathological results, the patients were divided into two groups: BPH without PI group (BPH group) and BPH with PI group. Statistical analysis was performed on clinical data, including age and body mass index (BMI), prostate volume (PV), postoperative residual urine volume (PVR), preoperative serum total prostate-specific antigen (tPSA), serum-free prostate-specific antigen (fPSA), preoperative and postoperative maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS) before and 3 months after surgery, quality of life index (QoL) before and 3 months after surgery, and postoperative complications.ResultsA total of 41 patients were included in this study, including 16 in the BPH group and 25 in the BPH with PI group. There were no significant differences in preoperative age, BMI, PV, PVR, tPSA, fPSA, and f/tPSA between the BPH and BPH with PI groups (P > 0.05). The preoperative mean Qmax of the BPH and BPH with PI groups were 9.44 ± 2.449 and 7.52 ± 2.946 [mean ± standard deviation (SD)] ml/s, mean IPSS were 17.75 ± 5.335 and 24.24 ± 5.861 (mean ± SD), and mean QoL were 4.13 ± 0.806 and 4.48 ± 0.8 (mean ± SD), respectively. The postoperative mean Qmax of the BPH and BPH with PI groups were 20.38 ± 4.787 and 14.32 ± 3.827 (mean ± SD) ml/s, mean IPSS were 2.69 ± 1.25 and 5.84 ± 3.579 (mean ± SD), and mean QoL were 0.13 ± 0.342 and 0.92 ± 0.759 (mean ± SD), respectively. In both groups, Qmax significantly increased (P < 0.05) and IPSS and QoL significantly decreased after HoLEP (P < 0.05). Before and after surgery, the Qmax in the BPH with PI group was lower than that in the BPH group, and the IPSS and QoL levels in the BPH with PI group were higher than those in the BPH group (P < 0.05). Compared with the BPH group, the increase in Qmax in the BPH with PI group was smaller and the decrease in IPSS was larger (P < 0.05), but the variation in QoL was not statistically significant (P > 0.05).ConclusionImprovements in Qmax, IPSS, and QoL in BPH patients with PI after HoLEP surgery were lower than those in BPH patients alone. PI may be a predictor of a worse response to surgical treatment. However, more multicenter randomized controlled trials with larger samples and long-term follow-up are needed to verify this. |
| first_indexed | 2024-04-11T00:40:29Z |
| format | Article |
| id | doaj.art-8ba2ca4161df44d39676b2b5aab46922 |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-04-11T00:40:29Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-8ba2ca4161df44d39676b2b5aab469222023-01-06T06:24:34ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2023-01-01910.3389/fsurg.2022.10266571026657Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research studyWeijian Zhou0Dongdong Mao1Liang Li2Gang Liu3Guojun Gao4Haikun Li5Dianjun Gao6Department of Clinical Medicine, Weifang Medical University, Weifang, ChinaDepartment of Urology, Affiliated Hospital of Weifang Medical University, Weifang, ChinaDepartment of Urology, Affiliated Hospital of Weifang Medical University, Weifang, ChinaDepartment of Urology, Affiliated Hospital of Weifang Medical University, Weifang, ChinaDepartment of Urology, Affiliated Hospital of Weifang Medical University, Weifang, ChinaDepartment of Urology, Affiliated Hospital of Weifang Medical University, Weifang, ChinaDepartment of Clinical Medicine, Weifang Medical University, Weifang, ChinaObjectiveTo investigate the clinical efficacy of holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH) with prostatic inflammation (PI).MethodsWe prospectively collected and followed up data on patients with BPH who underwent HoLEP at the Affiliated Hospital of Weifang Medical University between July 2021 and July 2022. According to the postoperative pathological results, the patients were divided into two groups: BPH without PI group (BPH group) and BPH with PI group. Statistical analysis was performed on clinical data, including age and body mass index (BMI), prostate volume (PV), postoperative residual urine volume (PVR), preoperative serum total prostate-specific antigen (tPSA), serum-free prostate-specific antigen (fPSA), preoperative and postoperative maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS) before and 3 months after surgery, quality of life index (QoL) before and 3 months after surgery, and postoperative complications.ResultsA total of 41 patients were included in this study, including 16 in the BPH group and 25 in the BPH with PI group. There were no significant differences in preoperative age, BMI, PV, PVR, tPSA, fPSA, and f/tPSA between the BPH and BPH with PI groups (P > 0.05). The preoperative mean Qmax of the BPH and BPH with PI groups were 9.44 ± 2.449 and 7.52 ± 2.946 [mean ± standard deviation (SD)] ml/s, mean IPSS were 17.75 ± 5.335 and 24.24 ± 5.861 (mean ± SD), and mean QoL were 4.13 ± 0.806 and 4.48 ± 0.8 (mean ± SD), respectively. The postoperative mean Qmax of the BPH and BPH with PI groups were 20.38 ± 4.787 and 14.32 ± 3.827 (mean ± SD) ml/s, mean IPSS were 2.69 ± 1.25 and 5.84 ± 3.579 (mean ± SD), and mean QoL were 0.13 ± 0.342 and 0.92 ± 0.759 (mean ± SD), respectively. In both groups, Qmax significantly increased (P < 0.05) and IPSS and QoL significantly decreased after HoLEP (P < 0.05). Before and after surgery, the Qmax in the BPH with PI group was lower than that in the BPH group, and the IPSS and QoL levels in the BPH with PI group were higher than those in the BPH group (P < 0.05). Compared with the BPH group, the increase in Qmax in the BPH with PI group was smaller and the decrease in IPSS was larger (P < 0.05), but the variation in QoL was not statistically significant (P > 0.05).ConclusionImprovements in Qmax, IPSS, and QoL in BPH patients with PI after HoLEP surgery were lower than those in BPH patients alone. PI may be a predictor of a worse response to surgical treatment. However, more multicenter randomized controlled trials with larger samples and long-term follow-up are needed to verify this.https://www.frontiersin.org/articles/10.3389/fsurg.2022.1026657/fullbenign prostatic hyperplasiaprostatic inflammationHoLEPclinical efficacyprospective research |
| spellingShingle | Weijian Zhou Dongdong Mao Liang Li Gang Liu Guojun Gao Haikun Li Dianjun Gao Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study Frontiers in Surgery benign prostatic hyperplasia prostatic inflammation HoLEP clinical efficacy prospective research |
| title | Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study |
| title_full | Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study |
| title_fullStr | Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study |
| title_full_unstemmed | Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study |
| title_short | Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study |
| title_sort | clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation a prospective research study |
| topic | benign prostatic hyperplasia prostatic inflammation HoLEP clinical efficacy prospective research |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2022.1026657/full |
| work_keys_str_mv | AT weijianzhou clinicalanalysisoftransurethralholmiumlaserenucleationinthetreatmentofbenignprostatichyperplasiawithprostaticinflammationaprospectiveresearchstudy AT dongdongmao clinicalanalysisoftransurethralholmiumlaserenucleationinthetreatmentofbenignprostatichyperplasiawithprostaticinflammationaprospectiveresearchstudy AT liangli clinicalanalysisoftransurethralholmiumlaserenucleationinthetreatmentofbenignprostatichyperplasiawithprostaticinflammationaprospectiveresearchstudy AT gangliu clinicalanalysisoftransurethralholmiumlaserenucleationinthetreatmentofbenignprostatichyperplasiawithprostaticinflammationaprospectiveresearchstudy AT guojungao clinicalanalysisoftransurethralholmiumlaserenucleationinthetreatmentofbenignprostatichyperplasiawithprostaticinflammationaprospectiveresearchstudy AT haikunli clinicalanalysisoftransurethralholmiumlaserenucleationinthetreatmentofbenignprostatichyperplasiawithprostaticinflammationaprospectiveresearchstudy AT dianjungao clinicalanalysisoftransurethralholmiumlaserenucleationinthetreatmentofbenignprostatichyperplasiawithprostaticinflammationaprospectiveresearchstudy |